France-headquartered Servier, an independent international pharmaceutical group governed by a foundation, has acquired Nasdaq-listed Day One Biopharmaceuticals, a biopharmaceutical company developing and commercialising targeted therapies for people of all ages with life-threatening diseases. The acquisition strengthens Servier’s position in low-grade glioma and in oncology with the addition of a marketed product and pipeline focused on rare cancers.
Servier paid US$21.50 per share for a total equity value of approximately US$2.5bn.
“The acquisition represents a step forward in Servier’s 2030 ambition to strengthen its position in rare cancers, and more specifically in paediatric low-grade glioma,” said Olivier Laureau, president of Servier.
Servier aims to become a leading innovator in oncology and neurology. It has more than 20,000 employees and a distributes medicines in more than 130 countries. In the 2024/25 financial year, the group achieved revenues of €6.9bn.
As of 31 December, 2024, Day One had 181 full-time employees and reported total revenues of US$131m.
Press release: Servier completes the acquisition of Day One Biopharmaceuticals
